ADGRL3 and attention deficit-hyperactivity disorder: For example, a disrupted YY1-binding site in a brain-specific enhancer of ADGRL3 creates a predisposition to attention-deficit/hyperactivity disorder (ADHD) (Martinez et al., 2016).